TABLE 1.
Value | OP | OR | CON | OP + 3- ROSI | OR + 3- ROSI | CON + 3- ROSI | OP + 6- ROSI | OR + 6- ROSI | CON + 6- ROSI |
---|---|---|---|---|---|---|---|---|---|
Body weight, g | 484 ± 15 (9) | 402 ± 13* (8) | 380 ± 9* (8) | 491 ± 8 (9) | 432 ± 4* (8) | 451 ± 14† (3) | 488 ± 8 (6) | 416 ± 8* (5) | 436 ± 11*† (6) |
MAP, mm Hg | 101 ± 6 (5) | 103 ± 6 (5) | 99 ± 3 (5) | 106 ± 3 (7) | 100 ± 3 (5) | 97 ± 2 (3) | 107 ± 3 (5) | 102 ± 3 (5) | 110 ± 5 (5) |
HR, bpm | 353 ± 19 (5) | 364 ± 4 (5) | 356 ± 12 (5) | 348 ± 16 (7) | 334 ± 7 (5) | 351 ± 5 (3) | 343 ± 14 (5) | 344 ± 7 (5) | 337 ± 10 (5) |
Blood glucose, mg/dl | 94 ± 3 (8) | 92 ± 3 (8) | 89 ± 2 (8) | 99 ± 4 (9) | 93 ± 3 (8) | 89 ± 6 (3) | 91 ± 3 (6) | 90 ± 2 (5) | 93 ± 2 (6) |
, P < 0.05 compared with similarly treated OP rats.
, P < 0.05 significant effect of rosiglitazone within group.